Cargando…
Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures
IMPORTANCE: Currently, rates of referral of patients with peritoneal metastasis in the United States who qualify for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are low, in part because of the misperception of high morbidity and mortality rates. However,...
Autores principales: | Foster, Jason M., Sleightholm, Richard, Patel, Asish, Shostrom, Valerie, Hall, Bradley, Neilsen, Beth, Bartlett, David, Smith, Lynette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484874/ https://www.ncbi.nlm.nih.gov/pubmed/30646202 http://dx.doi.org/10.1001/jamanetworkopen.2018.6847 |
Ejemplares similares
-
A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion
por: Haslinger, Michelle, et al.
Publicado: (2013) -
Cytoreduction with hyperthermic intraperitoneal chemotherapy: An anaesthetic challenge
por: Murughan, Kavita, et al.
Publicado: (2014) -
Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
por: Lei, Ziying, et al.
Publicado: (2020) -
Fluid administration in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: neither too much nor too little
por: Castellanos Garijo, Maria Elvira, et al.
Publicado: (2021) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
por: Gamboa, Adriana C., et al.
Publicado: (2019)